—Researchers in Canada compared isolated axial psoriatic arthritis, axial PsA with peripheral involvement, and isolated axial ankylosing spondylitis with psoriasis, to determine which factors predict ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved bimekizumab-bkzx for three new indications — PsA, AS and non-radiographic axial SpA. The ...
Share on Facebook. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window This nationwide cohort study involved the French national ...
With three new indications, BIMZELX® (bimekizumab-bkzx) is the first and only IL-17A and IL-17F inhibitor approved in the U.S. for the treatment of four chronic immune-mediated inflammatory diseases ...
· There are few treatments available for AS and 40% of patients have poor or no response to standard of care anti-TNFs2 Basel, June 10, 2015 – Novartis announced today new one-year study results from ...
Medically reviewed by Anita C. Chandrasekaran, MD Females often experience ankylosing spondylitis (AS) differently from ...
UCB (OTCPK:UCBJY) (OTCPK:UCBJF) said it has received FDA approval for its drug Bimzelx for the treatment of active psoriatic arthritis, active ankylosing spondylitis, and non-radiographic axial ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There were no new safety signals, while all fungal ...
Although other joints can be involved, ankylosing spondylitis (AS) primarily affects your spine. In this particular type of arthritis, the joints and ligaments of your spine become inflamed. This can ...
Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints (those between the spine and hipbone). Less commonly, AS can affect other joints such ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results